Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 143

1.

Gender bias in CIHR Foundation grant awarding.

Giannakeas V, Sopik V, Narod S.

Lancet. 2019 Jun 1;393(10187):2195. doi: 10.1016/S0140-6736(19)31103-1. No abstract available.

PMID:
31162072
2.

BARD1 is A Low/Moderate Breast Cancer Risk Gene: Evidence Based on An Association Study of the Central European p.Q564X Recurrent Mutation.

Suszynska M, Kluzniak W, Wokolorczyk D, Jakubowska A, Huzarski T, Gronwald J, Debniak T, Szwiec M, Ratajska M, Klonowska K, Narod S, Bogdanova N, Dörk T, Lubinski J, Cybulski C, Kozlowski P.

Cancers (Basel). 2019 May 28;11(6). pii: E740. doi: 10.3390/cancers11060740.

3.

Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk.

Reid BM, Permuth JB, Chen YA, Fridley BL, Iversen ES, Chen Z, Jim H, Vierkant RA, Cunningham JM, Barnholtz-Sloan JS, Narod S, Risch H, Schildkraut JM, Goode EL, Monteiro AN, Sellers TA.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1117-1126. doi: 10.1158/1055-9965.EPI-18-0833. Epub 2019 Apr 4.

PMID:
30948450
4.

Computer-Assisted Flagging of Individuals at High Risk of Colorectal Cancer in a Large Health Maintenance Organization Using the ColonFlag Test.

Goshen R, Choman E, Ran A, Muller E, Kariv R, Chodick G, Ash N, Narod S, Shalev V.

JCO Clin Cancer Inform. 2018 Dec;2:1-8. doi: 10.1200/CCI.17.00130.

5.

Association Between Invasive Lobular Breast Cancer and Mutations in the Mismatch Repair Gene MSH6.

Narod S.

JAMA Oncol. 2019 Jan 1;5(1):120. doi: 10.1001/jamaoncol.2018.6908. No abstract available.

PMID:
30629137
6.

The cost of treatment and its related complications for men who receive surgery or radiation therapy for prostate cancer.

Garbens A, Wallis CJD, Matta R, Kodama R, Herschorn S, Narod S, Nam RK.

Can Urol Assoc J. 2018 Dec 3:E236-E248. doi: 10.5489/cuaj.5598. [Epub ahead of print]

PMID:
30526806
7.

Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.

Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.

Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.

PMID:
30232083
8.

Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2.

Narod S, Sopik V, Cybulski C.

JAMA Oncol. 2018 Jul 1;4(7):1012. doi: 10.1001/jamaoncol.2018.0595. No abstract available.

PMID:
29801022
9.

Population-Based Genetic Testing for BRCA1 and BRCA2.

Narod S, Akbari MR.

J Clin Oncol. 2018 Feb 10;36(5):517. doi: 10.1200/JCO.2017.75.8490. Epub 2018 Jan 2. No abstract available.

PMID:
29293388
10.

Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.

Narod S, Booth CM, Foulkes WD.

N Engl J Med. 2017 Nov 2;377(18):1792. doi: 10.1056/NEJMc1711644. No abstract available.

PMID:
29094857
11.

Breast Cancer Genetics for Plastic Surgeons.

McInerney NM, Narod S, Metcalfe K, Semple J, Brown MH.

Plast Reconstr Surg. 2017 Sep;140(3):455-460. doi: 10.1097/PRS.0000000000003577. Review.

PMID:
28841602
12.

Survival Differences in Women with and without Autologous Breast Reconstruction after Mastectomy for Breast Cancer.

L Semple J, Metcalfe K, Shoukat F, Sun P, Narod S.

Plast Reconstr Surg Glob Open. 2017 Apr 3;5(4):e1281. doi: 10.1097/GOX.0000000000001281. eCollection 2017 Apr.

13.

Serum folate concentration and the incidence of lung cancer.

Durda K, Kąklewski K, Gupta S, Szydłowski M, Baszuk P, Jaworska-Bieniek K, Sukiennicki G, Kaczmarek K, Waloszczyk P, Narod S, Lubiński J, Jakubowska A.

PLoS One. 2017 May 11;12(5):e0177441. doi: 10.1371/journal.pone.0177441. eCollection 2017.

14.

Response.

Kotsopoulos J, Sun P, Narod S.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx039. No abstract available.

PMID:
28383664
15.

A high frequency of PALB2 mutations in Jamaican patients with breast cancer.

Lerner-Ellis J, Donenberg T, Ahmed H, George S, Wharfe G, Chin S, Lowe D, Royer R, Zhang S, Narod S, Hurley J, Akbari MR.

Breast Cancer Res Treat. 2017 Apr;162(3):591-596. doi: 10.1007/s10549-017-4148-1. Epub 2017 Feb 13.

PMID:
28194609
16.

Why Some Mastectomy Patients Opt to Undergo Delayed Breast Reconstruction: Results of a Long-Term Prospective Study.

Metcalfe KA, Semple J, Quan ML, Holloway C, Wright F, Narod S, Hofer S, Bagher S, Zhong T.

Plast Reconstr Surg. 2017 Feb;139(2):267-275. doi: 10.1097/PRS.0000000000002943.

PMID:
28121851
17.

Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?

Narod S, Sopik V.

Gynecol Oncol. 2017 Feb;144(2):238-240. doi: 10.1016/j.ygyno.2016.11.046. Epub 2016 Dec 22. No abstract available.

PMID:
28017307
18.

Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration.

Permuth JB, Reid B, Earp M, Chen YA, Monteiro AN, Chen Z; AOCS Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vanderstichele A, Van Niewenhuyse E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Moysich K, Odunsi K, Goodman MT, Shvetsov YB, Wilkens LR, Thompson PJ, Dörk T, Bogdanova N, Butzow R, Nevanlinna H, Pelttari L, Leminen A, Modugno F, Edwards RP, Ness RB, Kelley J, Heitz F, Karlan B, Lester J, Kjaer SK, Jensen A, Giles G, Hildebrandt M, Liang D, Lu KH, Wu X, Levine DA, Bisogna M, Berchuck A, Cramer DW, Terry KL, Tworoger SS, Poole EM, Bandera EV, Fridley B, Cunningham J, Winham SJ, Olson SH, Orlow I, Bjorge L, Kiemeney LA, Massuger L, Pejovic T, Moffitt M, Le N, Cook LS, Brooks-Wilson A, Kelemen LE, Gronwald J, Lubinski J, Wentzensen N, Brinton LA, Lissowska J, Yang H, Hogdall E, Hogdall C, Lundvall L, Pharoah PD, Song H, Campbell I, Eccles D, McNeish I, Whittemore A, McGuire V, Sieh W, Rothstein J, Phelan CM, Risch H, Narod S, McLaughlin J, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Kupryjanczyk J, Dansonka-Mieszkowska A, Schildkraut JM, Cheng JQ, Goode EL, Sellers TA.

Oncotarget. 2016 Nov 8;7(45):72381-72394. doi: 10.18632/oncotarget.10546.

19.

Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland.

Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz-Zaniewska D, Skotnicki P, Byrski T, Blecharz P, Marczyk E, Cedrych I, Jakubowicz J, Lubiński J, Sopik V, Narod S, Pierzchalski P.

Hered Cancer Clin Pract. 2016 Feb 3;14:5. doi: 10.1186/s13053-016-0046-5. eCollection 2016.

20.

Can advanced-stage ovarian cancer be cured?

Narod S.

Nat Rev Clin Oncol. 2016 Apr;13(4):255-61. doi: 10.1038/nrclinonc.2015.224. Epub 2016 Jan 20. Review.

PMID:
26787282

Supplemental Content

Loading ...
Support Center